NCT05436639View on ClinicalTrials.gov

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

February 18, 2025

Conditions
Autonomous Cortisol Secretion (ACS)ACTH-Independent Cushing SyndromeACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
DRUG

SPI-62 dose

SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).

Trial Locations (5)

11863

Institutul National de Endocrinologie, Bucharest

43210

Ohio State McCampbell Outpatient Care, Columbus

55905

Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester

500283

C.M.D.T.A. Neomed, Brasov

SW9 8RR

King's College Hospital, London

Sponsors
All Listed Sponsors
lead

Sparrow Pharmaceuticals

INDUSTRY

NCT05436639 - SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | Biotech Hunter | Biotech Hunter